TROV Share Price

Open 1.19 Change Price %
High 1.33 1 Day 0.35 36.84
Low 1.10 1 Week 0.36 38.30
Close 1.30 1 Month 0.56 75.68
Volume 7164438 1 Year -3.50 -72.92
52 Week High 5.98
52 Week Low 0.61
TROV Important Levels
Resistance 2 1.51
Resistance 1 1.43
Pivot 1.24
Support 1 1.17
Support 2 1.09
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.24 -11.11%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
ORCL 50.30 8.57%
ORCL 50.30 8.57%
ORCL 50.30 8.57%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
GCFB 0.95 58.33%
FALC 0.38 52.00%
LOCM 0.09 50.00%
ENOC 7.65 41.67%
TROV 1.30 36.84%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AMRS 3.29 21.40%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
PTSX 0.12 -40.00%
More..

TrovaGene, Inc. (NASDAQ: TROV)

TROV Technical Analysis 2.5
As on 22nd Jun 2017 TROV Share Price closed @ 1.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.71 & Strong Buy for SHORT-TERM with Stoploss of 0.86 we also expect STOCK to react on Following IMPORTANT LEVELS.
TROV Target for June
1st Target up-side 0.83
2nd Target up-side 0.96
3rd Target up-side 1.09
1st Target down-side 0.45
2nd Target down-side 0.32
3rd Target down-side 0.19
TROV Other Details
Segment EQ
Market Capital 54819236.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.trovagene.com
TROV Address
TROV
11055 Flintkote Avenue
Suite B
San Diego, CA 92121
United States
Phone: 858-952-7570
TROV Latest News
Interactive Technical Analysis Chart TrovaGene, Inc. ( TROV NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on TrovaGene, Inc.
TROV Business Profile
TrovaGene, Inc. (TrovaGene) is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�s urine-based test addresses market needs, such as women�s healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).